Association between CTLA-4 60G/A and -1661A/G polymorphisms and the risk of cancers: A meta-analysis

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Yan, Qing ^a   Chen, Pin ^a   Lu, Ailin ^a   Zhao, Peng ^a   Gu, Aihua ^b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Nanjing Medical University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

GENETIC PREDISPOSITION; GENETICS; HUMAN; META ANALYSIS; NEOPLASM; SINGLE NUCLEOTIDE POLYMORPHISM;

CTLA-4 ANTIGEN; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84893480136     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083710     Document Type: Article

References (45)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Pharoah PD, Dunning AM, Ponder BA, Easton DF (2004) Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer 4: 850-860. (Pubitemid 39472952)
3. Hoeijmakers JH (2001) Genome maintenance mechanisms for preventing cancer. Nature 411: 366-374.
4. Cooper JD, Duffin J, Zapol WM (1975) Cannulation of ascending aorta for long-term membrane oxygenator support. J Thorac Cardiovasc Surg 69: 905-908.
5. Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271: 1734-1736. (Pubitemid 26102823)
6. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, et al. (2011) Pillars article: CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994. 1: 405-413. J Immunol 187: 3466-3474.
7. Sun T, Hu Z, Shen H, Lin D (2009) Genetic polymorphisms in cytotoxic T-lymphocyte antigen 4 and cancer: the dialectical nature of subtle human immune dysregulation. Cancer Res 69: 6011-6014.
8. Egen JG, Kuhns MS, Allison JP (2002) CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 3: 611-618. (Pubitemid 34752469)
9. O'Day SJ, Hamid O, Urba WJ (2007) Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 110: 2614-2627. (Pubitemid 350250330)
10. Menard C, Ghiringhelli F, Roux S, Chaput N, Mateus C, et al. (2008) Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab? Clin Cancer Res 14: 5242-5249.
11. Hou R, Cao B, Chen Z, Li Y, Ning T, et al. (2010) Association of cytotoxic T lymphocyte-associated antigen-4 gene haplotype with the susceptibility to gastric cancer. Mol Biol Rep 37: 515-520.
12. Hadinia A, Hossieni SV, Erfani N, Saberi-Firozi M, Fattahi MJ, et al. (2007) CTLA-4 gene promoter and exon 1 polymorphisms in Iranian patients with gastric and colorectal cancers. J Gastroenterol Hepatol 22: 2283-2287. (Pubitemid 350145629)
13. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188. (Pubitemid 17189972)
14. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748.
15. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558. (Pubitemid 34746062)
16. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560. (Pubitemid 37088507)
17. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634. (Pubitemid 27387172)
18. Chuang WY, Strobel P, Gold R, Nix W, Schalke B, et al. (2005) A CTLA4high genotype is associated with myasthenia gravis in thymoma patients. Ann Neurol 58: 644-648. (Pubitemid 41377232)
19. Cheng TY, Lin JT, Chen LT, Shun CT, Wang HP, et al. (2006) Association of T-cell regulatory gene polymorphisms with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 24: 3483-3489.
20. Cozar JM, Romero JM, Aptsiauri N, Vazquez F, Vilchez JR, et al. (2007) High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. Hum Immunol 68: 698-704. (Pubitemid 47126657)
21. Wang L, Li D, Fu Z, Li H, Jiang W (2007) Association of CTLA-4 gene polymorphisms with sporadic breast cancer in Chinese Han population. BMC Cancer 7: 173.
22. Li H, Fu ZK, Wang LH, Li DL, Wu N, et al. (2008) [Association of cytotoxic T lymphocyte antigen-4 gene polymorphisms with susceptibility to breast cancer]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 24: 282-284.
23. Welsh MM, Applebaum KM, Spencer SK, Perry AE, Karagas MR, et al. (2009) CTLA4 variants, UV-induced tolerance, and risk of non-melanoma skin cancer. Cancer Res 69: 6158-6163.
24. Bouwhuis MG, Gast A, Figl A, Eggermont AM, Hemminki K, et al. (2010) Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis? Cancer Immunol Immunother 59: 303-312.
25. Khaghanzadeh N, Erfani N, Ghayumi MA, Ghaderi A (2010) CTLA4 gene variations and haplotypes in patients with lung cancer. Cancer Genet Cytogenet 196: 171-174.
26. Liu Y, He Z, Feng D, Shi G, Gao R, et al. (2011) Cytotoxic T-lymphocyte antigen-4 polymorphisms and susceptibility to osteosarcoma. DNA Cell Biol 30: 1051-1055.
27. Karabon L, Pawlak E, Tomkiewicz A, Jedynak A, Passowicz-Muszynska E, et al. (2011) CTLA-4, CD28, and ICOS gene polymorphism associations with non-small-cell lung cancer. Hum Immunol 72: 947-954.
28. Karabon L, Pawlak-Adamska E, Tomkiewicz A, Jedynak A, Kielbinski M, et al. (2012) Variations in suppressor molecule ctla-4 gene are related to susceptibility to multiple myeloma in a polish population. Pathol Oncol Res 18: 219-226.
29. Li D, Zhang Q, Xu F, Fu Z, Yuan W, et al. (2012) Association of CTLA-4 gene polymorphisms with sporadic breast cancer risk and clinical features in Han women of northeast China. Mol Cell Biochem 364: 283-290.
30. Erfani N, Haghshenas MR, Hoseini MA, Hashemi SB, Khademi B, et al. (2012) Strong Association of CTLA-4 Variation (CT60A/G) and CTLA-4 Haplotypes with Predisposition of Iranians to Head and Neck Cancer. Iran J Immunol 9: 188-198.
31. Bharti V, Mohanti BK, Das SN (2013) Functional genetic variants of CTLA-4 and risk of tobacco-related oral carcinoma in high-risk North Indian population. Hum Immunol 74: 348-352.
32. Feng D, Yang X, Li S, Liu T, Wu Z, et al. (2013) Cytotoxic T-lymphocyte antigen-4 genetic variants and risk of Ewing's sarcoma. Genet Test Mol Biomarkers 17: 458-463.
33. Khorshied MM, Gouda HM, Khorshid OM (2013) Association of cytotoxic T-lymphocyte antigen 4 genetic polymorphism, hepatitis C viral infection and B-cell non-Hodgkin lymphoma: an Egyptian study. Leuk Lymphoma.
34. Liu J, Song B, Wang T, Liu Y, Hao J, et al. (2013) Genetic variations in CTLA-4, TNF-alpha, and LTA and susceptibility to T-cell lymphoma in a Chinese population. Cancer Epidemiol.
35. Kammerer PW, Toyoshima T, Schoder F, Kammerer P, Kuhr K, et al. (2010) Association of T-cell regulatory gene polymorphisms with oral squamous cell carcinoma. Oral Oncol 46: 543-548.
36. Rahimifar S, Erfani N, Sarraf Z, Ghaderi A (2010) ctla-4 gene variations may influence cervical cancer susceptibility. Gynecol Oncol 119: 136-139.
37. Cheng XL, Ning T, Xu CQ, Li Y, Zhu BS, et al. (2011) Haplotype analysis of CTLA4 gene and risk of esophageal squamous cell carcinoma in Anyang area of China. Hepatogastroenterology 58: 432-437.
38. Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22: 329-360. (Pubitemid 38680426)
39. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3: 991-998. (Pubitemid 35363648)
40. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G (2006) Inflammation and cancer: how hot is the link? Biochem Pharmacol 72: 1605-1621. (Pubitemid 44666739)
41. Scheipers P, Reiser H (1998) Fas-independent death of activated CD4(+) T lymphocytes induced by CTLA-4 crosslinking. Proc Natl Acad Sci U S A 95: 10083-10088.
42. Beissert S, Bluestone JA, Mindt I, Voskort M, Metze D, et al. (1999) Reduced ultraviolet-induced carcinogenesis in mice with a functional disruption in B7-mediated costimulation. J Immunol 163: 6725-6731.
43. Ueda H, Howson JM, Esposito L, Heward J, Snook H, et al. (2003) Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423: 506-511. (Pubitemid 36648570)
44. Hernandez J, Ko A, Sherman LA (2001) CTLA-4 blockade enhances the CTL responses to the p53 self-tumor antigen. J Immunol 166: 3908-3914. (Pubitemid 32224917)
45. Espenschied J, Lamont J, Longmate J, Pendas S, Wang Z, et al. (2003) CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model. J Immunol 170: 3401-3407. (Pubitemid 36302220)